OmniAb, Inc. Warrant 2022- on Omniab Inc OABIW 深 沪
等待开盘 08-10 09:30:00 美东时间
0.074
+0.029
+64.08%
华盛通- 最 高0.08
- 今 开0.05
- 成交量 3.08万股
- 最 低 0.05
- 昨 收 0.0451
- 总市值 0
- 52周最高 0.2675
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.04
- 委 比 -93.55%
- 总股本 --
- 历史最高 1.50
- 量 比 0
- 振 幅 66.52%
- 历史最低 0.04
- 每 手 1
- 风险率 0.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Friday. Shares of Natera Inc (NASDAQ:NTRA) rose sharply after the company reported better-than-expected quarterly financial results and raised its FY26 sales guidance above estimates. The company reported a second-quarter loss o...
08-08 03:35
OmniAb shares are trading higher after the company reported better-than-expected Q2 financial results. The company also raised its FY2026 sales guidance above estimates.
OmniAb shares are trading higher after the company reported better-than-expected Q2 financial results. The company also raised its FY2026 sales guidance above estimates.
08-07 23:33
OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est
OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 million-$36.000 million vs $30.807 million estimate.
08-07 04:24
OmniAb Q2 EPS $(0.05) Beats $(0.12) Estimate, Sales $13.415M Beat $4.693M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $13.415 million which b...
08-07 04:09
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASD...
07-28 02:30
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ...
07-27 19:07
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech AG and OmniAb, Inc. announce the advancement of their bispecific ADC (bsADC) program VXA-222, utilizing an "AND-gate" logic to target two solid tumor antigens. Following successful completion of OmniAb's discovery work, the program enters its next phase, combining OmniAb's antibody solutions with VERAXA's ADC linker technology. VERAXA will develop and validate the lead candidate, with exclusive rights to commercialize products inco...
07-27 11:00
OmniAb Names Amechi Nwachuku Chief Operating Officer
The latest update is out from OmniAb ( ($OABI) ). Effective July 13, 2026, Omni...
07-13 20:48
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has made significant progress in its BiTAC® platform for developing conditionally active T cell engagers and antibody-drug conjugates. The company plans to prioritize investments in BiTAC-based therapies, aiming to advance VXA-102 to IND/CTA readiness by early 2028. With four BiTAC programs targeting solid tumors and two bispecific ADCs, VERAXA is leveraging its differentiated technology to attract partnerships, especially follo...
07-06 11:00
